Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer
High-mobility group box 1 (HMGB1) is a nuclear protein that is known to be secreted into extracellular fluids from injured cells, activated macrophages, and tumor cells. The clinical correlation of circulating HMGB1 levels with various diseases including cancer has been reported. However, there is n...
Saved in:
Main Authors: | Kayoko Waki, Kouichiro Kawano, Naotake Tsuda, Kimio Ushijima, Kyogo Itoh, Akira Yamada |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2017/1423683 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients
by: Shigeru Yutani, et al.
Published: (2015-01-01) -
Oophoropexy for Recurrent Ovarian Torsion
by: Jennifer Hartley, et al.
Published: (2018-01-01) -
Immunotherapy in Recurrent Ovarian Cancer
by: Keyao Chen, et al.
Published: (2025-01-01) -
Adjuvants for peptide-based cancer vaccines
by: Willem W Overwijk, et al.
Published: (2016-09-01) -
Investigation of the Predictive Factors of Recurrent Ovarian Mucinous Cystadenoma
by: Aykut Ozcan, et al.
Published: (2024-08-01)